Passage BIO (PASG) Change in Account Payables (2019 - 2026)
Passage BIO (PASG) posted quarterly Change in Account Payables of $197000.0 for Q1 2026, down 72.49% year-over-year from $716000.0 in Q1 2025, and up 22.36% quarter-over-quarter from $161000.0 in Q4 2025.
Passage BIO (PASG) Change in Account Payables (2019 - 2026) Analysis & Trends
Passage BIO's Change in Account Payables history runs 8 years deep, the most recent figure standing at $197000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 72.49% year-over-year to $197000.0; the TTM figure through Mar 2026 stood at $1.4 million (up 694.32% YoY), while the FY2025 annual figure was $1.9 million, up 438.13% from the prior year.
- Change in Account Payables for Q1 2026 stood at $197000.0, up from $161000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $937000.0 in Q2 2025, with the low at -$3.7 million in Q3 2022.
- The 5-year median for Change in Account Payables is -$280000.0 (2022), against an average of -$393000.0.
- The sharpest annual moves came in 2022 and 2024: Change in Account Payables sank 473.28% in 2022, then soared 236.91% in 2024.
- Passage BIO's Change in Account Payables stood at -$433000.0 in 2022, then tumbled by 240.42% to -$1.5 million in 2023, then soared by 49.32% to -$747000.0 in 2024, then soared by 121.55% to $161000.0 in 2025, then climbed by 22.36% to $197000.0 in 2026.
- Business Quant data shows PASG's Change in Account Payables at $197000.0 in Q1 2026, $161000.0 in Q4 2025, and $66000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | -408,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -408,000.00 |
| Jun 30, 2026 | -408,000.00 |
| Mar 31, 2026 | 197,000.00 |
| Mar 31, 2026 | 197,000.00 |
| Dec 31, 2025 | 161,000.00 |
| Dec 31, 2025 | 161,000.00 |
| Sep 30, 2025 | 66,000.00 |
| Sep 30, 2025 | 66,000.00 |
| Jun 30, 2025 | 937,000.00 |
| Jun 30, 2025 | 937,000.00 |
| Mar 31, 2025 | 716,000.00 |
| Mar 31, 2025 | 716,000.00 |
| Dec 31, 2024 | -747,000.00 |
| Dec 31, 2024 | -747,000.00 |
| Sep 30, 2024 | 868,000.00 |
| Sep 30, 2024 | 868,000.00 |
| Jun 30, 2024 | -1.07 Mn |
| Jun 30, 2024 | -1.07 Mn |
| Mar 31, 2024 | 389,000.00 |
| Mar 31, 2024 | 389,000.00 |